Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

fool.com - Reuben Gregg Brewer - Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?
Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?
The Motley Fool –

Bristol Myers Squibb has an attractive 4.3% yield, and its P/E is below average for a drug maker. The pharma giant has a long history of successfully developing and marketing new drugs. Bristol Myers Squibb is facing a major patent expiration, but…

investors.com - RACHEL FOX - Biotech Stock Ascendis Pharma Triggers Sell Rule; Here's Why You Shouldn't Give Up On It Yet
Biotech Stock Ascendis Pharma Triggers Sell Rule; Here's Why You Shouldn't Give Up On It Yet
Investor's Business Daily –

Ascendis Pharma (ASND) triggered the 7% sell rule on Friday as shares sold off alongside the broader market. This is a sign that investors who bought the breakout on Nov. 13 should be out of the stock. But given the Danish drugmaker's strong…

yalibnan.com - AI is shrinking drug discovery timelines Big Pharma says - Ya Libnan
AI is shrinking drug discovery timelines Big Pharma says - Ya Libnan
Beirut –

Photo illustration – The purpose of slowing AI is to ensure that human wisdom and artificial intelligence continue advancing together toward a safer, healthier and more prosperous world. Artificial intelligence has sped up early-stage drug…

marketbeat.com - BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 34,980 Shares of Stock
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 34,980 Shares of Stock
MarketBeat –

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 34,980 shares of the business's stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $77.72, for a total transaction of…

alexberenson.substack.com - Alex Berenson - With measles rising, fighting the MMR vaccine hurts broader efforts to take on Big Pharma
With measles rising, fighting the MMR vaccine hurts broader efforts to take on Big Pharma
Unreported Truths –

(PART TWO on the resurgence of measles in the United States: Why exaggerating the risks of the measles vaccine is counterproductive. Part One, on what's really driving the rise in cases, is here.) Measles is back in the United States. And the…

variety.com - Udita Jhunjhunwala - Obese Monkey Becomes a Weight-Loss Drug Guinea Pig in 'Boltrim' at India's WAVES Film Bazaar
Obese Monkey Becomes a Weight-Loss Drug Guinea Pig in 'Boltrim' at India's WAVES Film Bazaar
Variety –

Director Ashish Aryan is presenting “ Boltrim,” a Hindi-English dark comedy about an obese monkey subjected to drug trials by a pharmaceutical giant developing a weight-loss injection, to the Co-Production Market at India's WAVES Film…

seekingalpha.com - Edmund Ingham - Pharvaris: Orally Available HAE Therapy Appears To Be Ideal All Court Player
Pharvaris: Orally Available HAE Therapy Appears To Be Ideal All Court Player
Seeking Alpha –

I see Pharvaris as an intriguing long-term Buy and Hold, supported by deucrictibant's oral dosing, clinical results and versatility. PHVS faces an April 23, 2027 FDA decision for on-demand treatment; prophylaxis data showed an 83% attack reduction…

cbsnews.com - Megan  Cerullo - Anthropic is betting AI can help conquer disease and generate big bucks in the bargain
Anthropic is betting AI can help conquer disease and generate big bucks in the bargain
CBS News –

Fresh off its record-setting initial public offering, Anthropic now must show investors that it can sustain growth and generate profits. The company has a plan for that: curing some of the world's gnarliest diseases. In its IPO prospectus…

fool.com - Reuben Gregg Brewer - Pfizer's Launched and Acquired Drugs Grew 32% in Q3 - and 3 Other Reasons to Buy the Stock Before 2027
Pfizer's Launched and Acquired Drugs Grew 32% in Q3 - and 3 Other Reasons to Buy the Stock Before 2027
The Motley Fool –

Pfizer is a well-respected drugmaker facing typical industry headwinds. The company is financially strong, and new drug development is slowly gaining traction. The stock offers a huge 6% yield, which management strongly backs. Pfizer (PFE -0.51%)…

thehindu.com -  The Hindu Bureau - Telangana's merchandise exports surge in 3-years of Congress regime
Telangana's merchandise exports surge in 3-years of Congress regime
The Hindu –

As the Revanth Reddy-led Congress government in Telangana completes three years in office, a comparison of the merchandise exports from State with the last three years of BRS regime show the exports are 68% higher. Compared to the ₹79,000…

zerohedge.com - Tyler Durden - The Real Story Behind The Measles Comeback That RFK Hit Pieces Leave Out
The Real Story Behind The Measles Comeback That RFK Hit Pieces Leave Out
Zero Hedge –

One of the primary propaganda strategies of the political left is retroactive scapegoating ; blaming problems they created on the people who took power after them. And the accusations stick even though simple research would prove the opposite. You…

fool.com - TMF Breakfast News - Breakfast News: When Tech Wobbles, Dividends Pay
Breakfast News: When Tech Wobbles, Dividends Pay
The Motley Fool –

Tech stocks have had a bumpy few weeks, to say the least. Before we continue this edition of Breakfast News, here are some words of wisdom from Fools: “When a sell-off is driven more by fear than by fundamentals, it often creates…

libyaherald.com - Sami Zaptia - Libya Medical Supply Organisation Announces January 2027 Conference
Libya Medical Supply Organisation Announces January 2027 Conference
Libya Herald –

Libya's state medical purchasing entity, the Medical Supply Organisation (MSO) is organizing the 'Libyan International Conference on Medical and Pharmaceutical Supply.' The event will be held at a leading Tripoli hotel from 16 to 17 January 2027.

marketbeat.com - Top Growth Stocks To Watch Today - November 20th
Top Growth Stocks To Watch Today - November 20th
MarketBeat –

Could Falling Yields Make REIT Stocks Worth a Second Look? Prologis, Ascendis Pharma A/S, Teledyne Technologies, Pershing Square, and Jersey Mike's are the five Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth…

oreilly.com - Tim O’Reilly - What Happened to Silicon Valley?
What Happened to Silicon Valley?
O'Reilly Media –

On October 16, 2026, I delivered the second Annual Margaret Levi Lecture in Political Economy in conjunction with the AI and History conference at Johns Hopkins University in Baltimore. This is my original lecture as written, which incorporates…

Receive a Daily briefing on Pharma Industry News

Get Started